SEC Comment Letter for eWELLNESS HEALTHCARE Corp (EWLL) (CIK 0001550020) — Feb 14, 2020

eWELLNESS HEALTHCARE Corp (EWLL) (CIK 0001550020)
Date: Feb. 14, 2020 · CIK: 0001550020 · Accession: 0000000000-20-001411

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-236274

Date

February 13, 2020

Author

Not clearly detected

Form

UPLOAD

Company

eWELLNESS HEALTHCARE Corp (EWLL) (CIK 0001550020)

Letter

February 13, 2020 Darwin Fogt Chief Executive Officer eWELLNESS HEALTHCARE CORPORATION 333 Las Olas Way, Suite 100 Ft. Lauderdale, FL 33301 Re:eWELLNESS HEALTHCARE CORPORATION Registration Statement on Form S-1 Filed February 5, 2020 Amendment No. 1 to Registration Statement on Form S-1 Filed February 6, 2020 File No. 333-236274 Dear Mr. Fogt: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Christine Westbrook at 202-551-5019 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Lawrence R. Lonergan, Esq.

Show Raw Text

February 13, 2020
Darwin Fogt
Chief Executive Officer
eWELLNESS HEALTHCARE CORPORATION
333 Las Olas Way, Suite 100
Ft. Lauderdale, FL 33301
Re:eWELLNESS HEALTHCARE CORPORATION
Registration Statement on Form S-1
Filed February 5, 2020
Amendment No. 1 to Registration Statement on Form S-1
Filed February 6, 2020
File No. 333-236274
Dear Mr. Fogt:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Christine Westbrook at 202-551-5019 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Lawrence R. Lonergan, Esq.

SecProbe.io